Dr David Propper

Senior Lecturer; Consultant Medical Oncologist
Group Leader
Email
Research Focus

Our group researches pancreatic tumour-stromal interactions and reprogramming in 3D and other laboratory models. We also focus on translational trials of stromal reprogramming, including through epigenetic targeting, immune therapies, and cytokine gene therapy.

Key Publications

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun (2020) 24;11(1):4841. PMID: 32973176

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer (2020) 122, 1760-1768. PMID: 32350413

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut (2019) 68(6):1052-1064. PMID: 30121627

The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAMindependent manner. Nat Commun (2018) 9(1):3279. PMID: 30115931

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol (2018) 19(4):562-578. PMID: 29611518

Major Funding
  • CRUK
  • Stand Up To Cancer/Lustgarten Foundation
  • MRC
  • Barts Charity
Themes/Keywords
Targeting Tumour Cells Clinical Trials Pancreatic Centre for Tumour Microenvironment
Research

Our group researches pancreatic tumour-stromal interactions and reprogramming in 3D and other laboratory models. We also focus on translational trials of stromal reprogramming, including through epigenetic targeting, immune therapies, and cytokine gene therapy.

Major Funding
  • CRUK
  • Stand Up To Cancer/Lustgarten Foundation
  • MRC
  • Barts Charity